ATE554772T1 - Pteridine als hcv-hemmer und verfahren zu ihrer herstellung - Google Patents

Pteridine als hcv-hemmer und verfahren zu ihrer herstellung

Info

Publication number
ATE554772T1
ATE554772T1 AT06777220T AT06777220T ATE554772T1 AT E554772 T1 ATE554772 T1 AT E554772T1 AT 06777220 T AT06777220 T AT 06777220T AT 06777220 T AT06777220 T AT 06777220T AT E554772 T1 ATE554772 T1 AT E554772T1
Authority
AT
Austria
Prior art keywords
pteridine
production
hcv inhibitors
hcv
inhibitors
Prior art date
Application number
AT06777220T
Other languages
English (en)
Inventor
Pierre Jean-Marie Bernard Raboisson
Dominique Louis Nestor Ghislain Surleraux
Tse-I Lin
Oliver Lenz
Kenneth Alan Simmen
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Application granted granted Critical
Publication of ATE554772T1 publication Critical patent/ATE554772T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06777220T 2005-05-12 2006-05-12 Pteridine als hcv-hemmer und verfahren zu ihrer herstellung ATE554772T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68039305P 2005-05-12 2005-05-12
EP05106212 2005-07-07
EP06075854 2006-04-06
PCT/EP2006/062289 WO2006120251A1 (en) 2005-05-12 2006-05-12 Pteridines useful as hcv inhibitors and methods for the preparation thereof

Publications (1)

Publication Number Publication Date
ATE554772T1 true ATE554772T1 (de) 2012-05-15

Family

ID=36593103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06777220T ATE554772T1 (de) 2005-05-12 2006-05-12 Pteridine als hcv-hemmer und verfahren zu ihrer herstellung

Country Status (14)

Country Link
US (5) US20090156595A1 (de)
EP (1) EP1881834B1 (de)
JP (1) JP5464685B2 (de)
KR (1) KR20080005978A (de)
AR (1) AR056347A1 (de)
AT (1) ATE554772T1 (de)
AU (1) AU2006245675B2 (de)
BR (1) BRPI0609101A2 (de)
CA (1) CA2608326C (de)
ES (1) ES2386461T3 (de)
IL (1) IL186750A (de)
MX (1) MX2007014081A (de)
PL (1) PL1881834T3 (de)
WO (1) WO2006120251A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007003923A0 (en) * 2004-09-30 2007-02-28 Tibotec Pharm Ltd Hcv inhibiting bi-cyclic pyrimidines
EP1869037B1 (de) * 2005-03-25 2011-07-27 Tibotec Pharmaceuticals Heterobicyclische inhibitoren von hvc
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
CN102702194A (zh) 2005-12-21 2012-10-03 雅培制药有限公司 抗病毒化合物
WO2008003149A2 (en) * 2006-07-06 2008-01-10 Gilead Sciences , Inc. Substituted pteridines for the treatment and prevention of viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
EP2539338A1 (de) * 2010-02-24 2013-01-02 Syngenta Participations AG Neue mikrobizide
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NZ729172A (en) 2013-01-31 2018-06-29 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
DK3097102T3 (en) 2015-03-04 2018-01-22 Gilead Sciences Inc TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO [3,2-D] PYRIMIDINE COMPOUNDS
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
MA46093A (fr) 2016-09-02 2021-05-19 Gilead Sciences Inc Composés modulateurs du recepteur de type toll
CN107501173B (zh) * 2017-08-17 2020-07-24 武汉桀升生物科技有限公司 一种在温和条件下合成4-烷胺基吡啶的方法
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789496A (de) * 1971-10-05 1973-03-29 S M B Anciens Ets J Muelberger
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000039129A1 (en) 1998-12-28 2000-07-06 K.U. Leuven Research & Development Immunosuppressive effects of pteridine derivatives
US7087399B1 (en) * 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
ATE449764T1 (de) 1999-12-28 2009-12-15 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
ES2266258T3 (es) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
JP4329003B2 (ja) 2001-03-23 2009-09-09 バイエル コーポレイション Ｒｈｏキナーゼ阻害剤
GB0127433D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
ES2289279T3 (es) 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated Composiciones utiles como inhibidores de proteinquinasas.
EP1485380B1 (de) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazine als proteinkinasehemmer
EP1485100B1 (de) 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azolylaminoazine als proteinkinasehemmer
EP1485381B8 (de) 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazine als inhibitoren von proteinkinasen
KR100516434B1 (ko) 2002-04-04 2005-09-22 (주) 비엔씨바이오팜 6-(4-치환된-아닐리노)피리미딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
WO2003097615A1 (en) * 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
US7491367B2 (en) * 2002-06-04 2009-02-17 Applera Corporation System and method for providing a standardized state interface for instrumentation
AU2003260072A1 (en) 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Antagonists of chemokine receptors
HK1077762A1 (zh) 2002-09-10 2006-02-24 Scios Inc. TFGß[转化生长因子]的抑制剂
US20040138188A1 (en) 2002-11-22 2004-07-15 Higgins Linda S. Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
JP2006524633A (ja) 2002-11-22 2006-11-02 サイオス・インコーポレーテツド β−アドレナリン作動性経路における病理学的変化を打ち消すための方法
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CA2520465A1 (en) * 2003-03-28 2004-10-14 Scios Inc. Bi-cyclic pyrimidine inhibitors of tgf.beta.
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
BRPI0511805A (pt) 2004-06-04 2008-01-15 Bioniche Life Sciences Inc uso de imatinib para tratar distúrbios hepáticos e infecções virais
AP2007003923A0 (en) * 2004-09-30 2007-02-28 Tibotec Pharm Ltd Hcv inhibiting bi-cyclic pyrimidines
WO2006105222A2 (en) 2005-03-25 2006-10-05 Scios Inc. Carboxamide inhibitors of tgfb
EP1869037B1 (de) * 2005-03-25 2011-07-27 Tibotec Pharmaceuticals Heterobicyclische inhibitoren von hvc
CN101189234B (zh) 2005-03-25 2011-08-17 泰博特克药品有限公司 Hcv的杂二环抑制剂
AR054122A1 (es) * 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas

Also Published As

Publication number Publication date
EP1881834B1 (de) 2012-04-25
CA2608326C (en) 2015-11-10
JP2008540493A (ja) 2008-11-20
US9290502B2 (en) 2016-03-22
KR20080005978A (ko) 2008-01-15
CA2608326A1 (en) 2006-11-16
ES2386461T3 (es) 2012-08-21
US20090156595A1 (en) 2009-06-18
JP5464685B2 (ja) 2014-04-09
IL186750A0 (en) 2008-02-09
US20160159803A1 (en) 2016-06-09
PL1881834T3 (pl) 2012-09-28
AR056347A1 (es) 2007-10-03
BRPI0609101A2 (pt) 2010-02-17
US9951075B2 (en) 2018-04-24
MX2007014081A (es) 2008-02-12
US20140094468A1 (en) 2014-04-03
US20170275288A1 (en) 2017-09-28
US20160158238A1 (en) 2016-06-09
US9708328B2 (en) 2017-07-18
AU2006245675A1 (en) 2006-11-16
EP1881834A1 (de) 2008-01-30
AU2006245675B2 (en) 2011-04-14
IL186750A (en) 2014-08-31
WO2006120251A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
ATE419260T1 (de) C-aryl-glucosid-sglt2-inhibitoren und verfahren zu ihrer herstellung
DE602006020386D1 (de) Duraimplantat und Verfahren zu seiner Herstellung
ATE459623T1 (de) Pyridoä2,3-düpyrimidine, die sich als hcv- inhibitoren eignen und verfahren zu deren herstellung
DE602006012283D1 (de) Integrierte schaltung und verfahren zu ihrer herstellung
EP1800317A4 (de) Isolatorbeschichtung und verfahren zu ihrer herstellung
DE602005020467D1 (de) Dielektrische luneberglinse und verfahren zu ihrer herstellung
EP1921674A4 (de) Halbleiterbauelement und verfahren zu seiner herstellung
ATE556077T1 (de) Tetrahydrochinolinderivate und verfahren zu deren herstellung
DE602006007336D1 (de) Umspritzte behälter und verfahren zu deren herstellung
EP1894626A4 (de) Homogener, hochdisperser metallkatalysator und verfahren zu seiner herstellung
DE602006004379D1 (de) Nanodraht-Struktur und Verfahren zu ihrer Herstellung
EP1876398A4 (de) Verzweigte kühlmittelrelaiseinheit und verfahren zu ihrer herstellung
DE102006057312A8 (de) Verbundrohr und Verfahren zu seiner Herstellung
EP1906468A4 (de) Batteriedose und verfahren zu ihrer herstellung
DE602005013692D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE502006005961D1 (de) Endoskop und Verfahren zu seiner Herstellung
DE502006003563D1 (de) Polyester-polysiloxan-copolymere und verfahren zu deren herstellung
ATE535510T1 (de) Benzylamine, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmende mittel
DE602006013001D1 (de) Zusammensetzung mit verbesserter stabilität und verfahren zu ihrer herstellung
DE602006012972D1 (de) Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
EP2163665A4 (de) Elastisches polyurethangarn und verfahren zu seiner herstellung
EP1820223A4 (de) Leuchtdiode und verfahren zu ihrer herstellung
EP1873798A4 (de) Kondensator und verfahren zu seiner herstellung
DE602006021029D1 (de) Filtermodul und verfahren zu dessen herstellung
DE602005026176D1 (de) Rollenlose spule und verfahren zu ihrer herstellung